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Abstract
The importance of chronic low-grade inflammation in the pathology of numerous age-related chronic conditions is now clear. An unre-
solved inflammatory response is likely to be involved from the early stages of disease development. The present position paper is the
most recent in a series produced by the International Life Sciences Institute’s European Branch (ILSI Europe). It is co-authored by the
speakers from a 2013 workshop led by the Obesity and Diabetes Task Force entitled ‘Low-grade inflammation, a high-grade challenge:
biomarkers and modulation by dietary strategies’. The latest research in the areas of acute and chronic inflammation and cardiometabolic,
gut and cognitive health is presented along with the cellular and molecular mechanisms underlying inflammation–health/disease associations.
The evidence relating diet composition and early-life nutrition to inflammatory status is reviewed. Human epidemiological and intervention
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Abbreviations: CNS, central nervous system; ILSI, International Life Sciences Institute; LPS, lipopolysaccharide; MetS, metabolic syndrome; NAFLD,
non-alcoholic fatty liver disease; RCT, randomised controlled trial; T2DM, type 2 diabetes mellitus.
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data are thus far heavily reliant on the measurement of inflammatory markers in the circulation, and in particular cytokines in the fasting
state, which are recognised as an insensitive and highly variable index of tissue inflammation. Potential novel kinetic and integrated
approaches to capture inflammatory status in humans are discussed. Such approaches are likely to provide a more discriminating
means of quantifying inflammation–health/disease associations, and the ability of diet to positively modulate inflammation and provide
the much needed evidence to develop research portfolios that will inform new product development and associated health claims.
Key words: Low-grade inflammation: Biomarkers: Chronic diseases: Health claims
Introduction and overview of the focus of the
position paper
Inflammation is a central component of innate (non-specific)
immunity. In generic terms, inflammation is a local response
to cellular injury that is marked by increased blood flow,
capillary dilatation, leucocyte infiltration, and the localised
production of a host of chemical mediators, which serves to
initiate the elimination of toxic agents and the repair of
damaged tissue(1). It is now clear that the termination (alter-
natively known as resolution) of inflammation is an active
process involving cytokines and other anti-inflammatory
mediators, particularly lipids, rather than simply being the
switching off of pro-inflammatory pathways(2,3).
Inflammation acts as both a ‘friend and foe’: it is an essential
component of immunosurveillance and host defence, yet a
chronic low-grade inflammatory state is a pathological feature
of a wide range of chronic conditions, such as the metabolic
syndrome (MetS), non-alcoholic fatty liver disease (NAFLD),
type 2 diabetes mellitus (T2DM) and CVD(4,5). Although the
association between inflammation and chronic conditions is
widely recognised, the issue of causality and the degree to
which inflammation contributes and serves as a risk factor
for the development of disease remain unresolved. As will
be discussed, part of this uncertainty is due to a general lack
of sensitive and specific biomarkers of low-grade chronic
inflammation that can be used in human trials(1).
The present article results from an International Life
Sciences Institute (ILSI) Europe Workshop held in September
2013 in Granada, Spain entitled ‘Low-grade inflammation a
high grade challenge: biomarkers and modulation by dietary
strategies’, and aims to serve as an update to existing reviews
in the area of inflammation and health and its assessment and
modulation(1,6,7). In particular, the present article will focus on
the latest research findings in the areas of inflammation and
cardiometabolic, cognitive and gut health, and how early-life
nutrition and the macronutrient and plant bioactive compo-
sition of the adult diet influence inflammatory processes. It
will discuss existing and emerging methods used to quantify
inflammatory status in humans. Importantly, the article will
identify knowledge gaps and methodological limitations that
need to be addressed.
Exploring the role of inflammation in health and
chronic diseases
Low-grade inflammation in cardiometabolic disease
The role of inflammation in the early-stage pathophysiology
of atherothrombotic events has been recognised for over
20 years. Leucocyte recruitment into the sub-endothelial
compartment of damaged arteries initiates a cascade of
events mediated by leucocyte-derived inflammatory medi-
ators. In particular, chemokines and cytokines propagate
atherosclerosis via (1) increased chemokine production and
expression of endothelial adhesion molecules, stimulating
further leucocyte recruitment, (2) promoting lipid-laden
foam-cell formation, (3) initiating smooth muscle cell prolifer-
ation, and (4) inducing plaque instability and eventual
rupture(8,9). The ensuing thrombosis is also in large part
dependent on the inflammatory status of the ruptured plaque.
In addition to a direct role on events within the arterial wall,
inflammation is an important determinant of the multi-organ
cardiometabolic dysfunction, and the increased risk of
T2DM, NAFLD and CVD associated with obesity(10). Adipose
tissue hypertrophy is associated with immune cell infiltration,
in particular that of macrophages and T cells, and a local pro-
inflammatory milieu wherein key cytokines including TNF-a,
IL-6 and IL-1b impede the insulin signalling cascade to
induce insulin resistance(11,12). This ultimately leads to a dys-
regulation of glucose and lipid metabolism in adipose tissue,
skeletal muscle and liver. However, up to 30 % of obese indi-
viduals are considered metabolically healthy (MHO)(13), and
there is evidence to suggest that a lack of the typical elevation
in the inflammatory profile associated with obesity may
underlie this ‘protected’ MHO phenotype. For example, in
morbidly obese individuals, Barbarroja and co-workers
observed mean homeostatic model assessment for insulin
resistance (HOMA-IR) scores (insulin sensitivity index) of
3·31 and 11·48 in subjects with MHO (BMI 55 kg/m2) or who
were metabolically unhealthy obese (BMI 56 kg/m2), respect-
ively, which was associated with a 2- to 4-fold greater adipose
expression of inflammatory cytokines (TNF-a, IL-1b and IL-6)
between the two obese groups(14).
Inflammation plays a direct role in the progression of
NAFLD, the most common liver disorder in Western countries.
NAFLD comprises a spectrum of conditions ranging from
benign steatosis to non-alcoholic steatohepatitis characterised
by hepatocyte injury (hepatocyte ballooning and Mallory
bodies) and necroinflammation, and potentially to progressive
fibrosis that can lead to cirrhosis(15,16). The pathological
progression of NAFLD is considered to have a two-hit basis
(Fig. 1). The first hit, hepatocyte accumulation of fat, is
thought to arise due to an increased delivery of fatty acids
to the hepatocyte, an increase in hepatocyte fatty acid and
TAG synthesis, and decreased fatty acid oxidation. The resul-
tant excess of fat may result in lipotoxicity and a pro-inflam-
matory and pro-oxidative state (the second hit), which
ultimately induces cellular senescence, which, if unchecked,
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leads to fibrosis and cirrhosis. Hepatic inflammation is
mediated via the activation of local macrophages called
Kupffer cells. Currently, no medication or surgical procedure
has been approved for treating NAFLD or non-alcoholic
steatohepatitis with confidence. Considering the overall lack
of success in curbing global trends in the prevalence of
excess body weight, inflammatory processes are emerging as
a strong therapeutic target to reduce the risk of T2DM, CVD
and NAFLD in obese individuals.
Gut–systemic inflammatory associations
With recent significant advances in the ability to characterise
the gut microbiota in increasing detail, comes the recognition
of the importance of the microbiota not only in gastrointestinal
health, but also in systemic metabolism and cardiometabolic
health, with the immune system and inflammatory processes
central to gut–systemic tissue ‘cross-talk’. The human intestine
contains 1 £ 1013 to 1 £ 1014 bacterial cells, which outnumber
human cells by a factor of 10 to 1 and contain approximately
150 times as many genes as the human genome(17). Increasing
evidence indicates that the microbiota is significantly altered
through the ageing process(18,19) and in obesity(18), with
a deleterious decline in microbiota ‘richness’ and gene
expression diversity evident in both situations(18).
Gastrointestinal tract–microbiota interactions influence host
health, and in particular immune function, by promoting the
development and maintenance of the mucosal immune
system, protecting against pathogen invasion and maintaining
gastrointestinal tract barrier integrity(20). Gut permeability to
bacterial lipopolysaccharides (LPS), a potent inflammatory
stimulant, appears to be an important trigger for low-grade
systemic inflammation. LPS are found on the outer
membrane of Gram-negative bacteria such as Proteobacteria
(e.g. Escherichia coli), and serve as an endotoxin. In the
elderly, a higher count of LPS-producing bacteria in the
colon, along with a lower abundance of bifidobacteria(21,22),
a combination which is thought to promote increased gut
permeability(21), is likely to lead to higher plasma levels
of LPS (termed metabolic endotoxaemia). Through the
interaction with Toll-like receptor 4 on mononuclear cells,
microbiota-derived LPS may be an important trigger in the
development of inflammation and metabolic diseases(23). In
a recent dietary intervention study in male C57Bl/6 mice, the
alteration in microbiota profiles as a result of a high-fat diet
was strongly associated with gut permeability, endotoxaemia
and adipose tissue inflammation(24).
In addition to its role in low-grade inflammatory cardiome-
tabolic conditions, emerging evidence is suggesting that the
gut microbiota can influence the risk of high-grade auto-
immune inflammatory conditions such as type 1 diabetes
mellitus, coeliac disease, inflammatory bowel disease and
rheumatoid arthritis(25–27), the incidence of which has risen
dramatically since the 1940s. These conditions are now
thought to affect 5–10 % of those in Western societies(28).
Certain members of the gut microbiota have been shown to
induce mimics of human antigens and trigger the production
of autoantibodies responsible for aberrant immune responses
to normal human proteins and hormones including leptin,
peptide YY and ghrelin(29). It is not unreasonable to speculate
that the adverse impact of the energy-dense, nutrient-poor
Western-style diet on human gut microbiota and immune
system, which have both been finely tuned and honed
by high-fibre, high-polyphenol traditional diets over the
millennia, may therefore be an important contributor to the
environmental stimuli that trigger and progress autoimmune
conditions(30). A possible starting point when discussing the
underlying mechanisms by which diets rich in whole plant
foods or fermentable fibres can have an impact on immune
function and tolerance may be the recent demonstration that
butyrate, an important fermentation end product produced
by the gut microbiota from fibre, controls human dendritic
cell maturation, a key process in immune homeostasis, since
dendritic cells are considered as ‘gate keepers’ of the immune
system(31,32). In addition, butyrate induces murine peripheral
regulatory T-cell generation(33), acetate affects neutrophil
chemotaxis and oxidative burst, butyrate inhibits adipocyte–
macrophage inflammatory interactions(34), and propionate
reduces the inflammatory output of adipose tissue(35). Probio-
tic, fibre or polyphenol up-regulation of microbial activities
that control both the quantity and profile of bile acids returning
to the liver via the enterohepatic circulation with their sub-
sequent regulation of farnesoid X receptor and TGR5 is also
emerging as an important pathway linking the gut microbiota
with extra-intestinal physiological/immune function(33,36,37).
Low-grade systemic inflammation and neuroinflammation
Communication between the systemic immune system and the
central nervous system (CNS) is a critical but often overlooked
component of the inflammatory response to tissue injury,
Obesity Insulin resistance
Type 2 diabetes
Steatosis
(fatty liver)
Steato-
hepatitis/
cirrhosis
Inflammation
Oxidative stress
Necrosis
Fibrosis
1st hit
2nd hit
Fig. 1. Two-hit model of non-alcoholic fatty liver disease.
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disease or infection. Activation of highly conserved neuronal
and hormonal communication pathways in mammals drives
diverse CNS-regulated components of the inflammatory
response, including fever, neurogenic inflammation, descend-
ing anti-inflammatory mechanisms and a coordinated set of
metabolic and behavioural changes, including fatigue, anhe-
donia, depression and mild cognitive impairment. These
behavioural changes are collectively referred to as ‘sickness
behaviour’(38–40). Experimental studies have provided evi-
dence that activation of microglia, the macrophages of the
CNS, as well as the cerebral vasculature, plays a key role in
the development of these behavioural changes, by inducing
pro-inflammatory mediators, such as IL-1b, TNF-a and PGE2
in the CNS(38,41,42).
Much of what we know is derived from studies using
mimetics of bacterial and viral infection. Depending on the
stimulus used, these mimetics induce a transient response in
otherwise healthy subjects; for example, administration of
LPS results in enhanced production of IL-6 (approximately
80-fold) and IL-1b (approximately 4-fold), peaking at 3 h
after a challenge and returning to baseline at 24 h(32). CNS
responses to (patho)physiological stimuli, such as genuine
infections or low-grade inflammation as a result of the MetS,
are less well described.
Development of sickness behaviour in response to an infec-
tion is part of the normal response to fighting infection, and
can occur during low-grade sub-pyrogenic inflammation(41);
however, these adaptive responses are not always harmless.
Microglia have a very low turnover, and it has been suggested
that these long-lived cells have an innate memory, resulting in
a prolonged and heightened response under neuroinflamma-
tory conditions(43). A normal part of the homeostatic signalling
from the periphery to the brain, therefore, has the potential
to have a profound impact on brain disease initiation or
progression(44,45). In a recent prospective clinical study,
Alzheimer’s disease patients were followed for 6 months and
assessed for the presence of circulating cytokines, episodes
of microbial infection and cognitive decline. Patients with
both high levels of TNF-a (.4·2 pg/ml) at baseline and
microbial infection during the assessment period showed a
4-fold greater cognitive decline, relative to patients with low
levels of TNF-a (,2·4 ng/ml) at baseline and no infections(46).
Raised serum levels of TNF-a and IL-6, but not CRP,
are also associated with increased frequency of other
common neuropsychiatric symptoms observed in Alzheimer’s
disease patients, including apathy, anxiety, depression and
agitation(47).
Recently, the effects of LPS and a real infection (Salmonella
typhimurium) on cerebral endothelial and microglial acti-
vation were compared. While LPS administration resulted in
a robust but transient neuroinflammatory response, a genuine
infection induced a prolonged pro-inflammatory cytokine
response in the CNS, leading to microglial priming(48).
A detailed consideration of the impact and mechanistic basis
for the association between neuroinflammation and neuronal
and overall CNS function, cognition and the risk of age-related
cognitive decline and dementia is outside the scope of the
present review, and has been the topic of many recent
expert review articles(49–54).
Collectively, these data highlight inflammatory pathways as
important targets for strategies promoting healthy brain ageing
and reducing the risk of age-related cognitive decline.
Dietary modulation of low-grade inflammation
There is a substantial amount of evidence to suggest that many
foods, nutrients and non-nutrient food components modulate
inflammation both acutely and chronically(1,6). However, diet-
ary studies have been typically limited to measuring a small
number of blood markers of inflammation, often in the fasting
state, and these may not necessarily reflect inflammation in
tissue compartments or what happens in response to inflam-
matory challenges. This presents a significant limitation to
our understanding of diet/nutrient–inflammation interactions.
Previous ILSI Europe activities have dealt extensively with the
food/nutrition–inflammation interaction(6,7), and it is beyond
the scope of the present review to provide a systematic or
extensive coverage of this area. Instead, some specific
examples will be discussed.
Dietary fats and inflammation
Dietary fatty acids may affect inflammatory processes through
effects on body weight and adipose tissue mass and via an
impact on membrane and lipid raft composition and function.
Within the cell, membrane-derived fatty acids and their deriva-
tives can influence inflammation by serving as modulators of
NF-kB and PPAR-a/g transcription factor pathways(55), and
as precursors for a host of eicosanoid and docosanoid
oxidation products produced via the action of epoxygenases,
lipoxygenases and cyclo-oxygenases(56). Also, recent advances
in the field have uncovered NLRP3 (NACHT, LRR and PYD
domains-containing protein 3) inflammasome activation and
IL-1b signalling as a key sensor of SFA-mediated metabolic
stress in obesity and T2DM(57) and EPA- and DHA-derived
resolvins and protectins that actively ameliorate a pro-inflam-
matory state(58). Obesity significantly reduced DHA-derived
17-hydroxydocosahexaenoic acid, a resolvin D1 precursor,
and protectin D1 in adipose tissue, which may in turn have
pro-inflammatory consequences(59). Also, dietary EPA/DHA
supplementation within an obesogenic dietary challenge
restored endogenous adipose resolvin and protectin bio-
synthesis, concomitant with attenuated adipose inflammation
and insulin resistance(59). An elegant human study showed
that a relatively high dose of LC n-3 PUFA augmented anti-
inflammatory eicosanoid secretion and attenuated inflamma-
tory gene expression in the subcutaneous adipose tissue of
severely obese non-diabetic patients(60). Thus, there is much
recent information on novel mechanisms of action by which
dietary fatty acids of different classes influence inflammatory
processes, some acting in pro-inflammatory and others in
anti-inflammatory or inflammation-resolving ways.
There is some evidence, albeit not always consistent, for
pro-inflammatory effects of dietary SFA(1). Much of this evi-
dence comes from either in vitro or cross-sectional studies,
A. M. Minihane et al.4
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and there are limited randomised controlled trial (RCT) exam-
ining changes in SFA intake and inflammation in humans. The
LIPGENE RCT investigated the effects of substituting dietary
SFA with MUFA or as part of a low-fat diet, with or without
LC n-3 PUFA supplementation, in subjects with the MetS(61).
While a low-fat n-3 PUFA-enriched diet significantly reduced
the risk of the MetS(62), modifying dietary fat had no significant
effect on key biomarkers of cardiometabolic risk including
insulin sensitivity and the plasma inflammatory markers
assessed(63). However, there was clear modulation of
NF-kB-mediated inflammation and oxidative stress in the
postprandial state according to lipid composition(64,65). This
lack of impact of LC n-3 PUFA on the fasting plasma inflam-
masome in humans(66) is in line with previous human
studies(63,67), but contradicts the effects observed in a wide
variety of cell and animal models. However, as will be dis-
cussed in the section ‘Translating research into public health
benefit and novel products’, it is difficult to know whether
the output from these RCT truly demonstrates a lack of effi-
cacy or reflects insufficient dose and/or duration or poor
selection of fasting plasma biomarkers of inflammation,
which are insensitive to physiologically meaningful changes
occurring in key metabolic tissues such as the liver and
adipose tissue.
As with other common phenotypes, there is evidence emer-
ging that the associations between dietary fat composition and
inflammation are influenced by common gene variants(68). In
the LIPGENE study, SNP in the genes encoding the anti-
inflammatory peptide adiponectin (ADIPOQ) and its receptor
(ADIPOR1) have been shown to interact with SFA to modulate
the effect of dietary fat modification on insulin resistance(69),
and using a case–control approach, it was observed that a
common SNP of the C3 gene was related to the risk of the
MetS, but more importantly, the impact of this was greatly
accentuated by high plasma levels of SFA(70). Also, the combi-
nation of polymorphisms in genes encoding IL-6, lymphotoxin
a (LTA) and TNF-a had an additive effect, which interacted
with plasma fatty acid status to modulate the risk of the
MetS(71). Grimble et al.(72) demonstrated that the ability of
LC n-3 PUFA to decrease TNF-a production is influenced by
inherent TNF-a production and by polymorphisms in the
TNF-a and LTA genes.
Inflammation in the postprandial state is likely to contribute
to the pathological impact of exaggerated postprandial
lipaemia(73). Although there has been some investigation of
the impact of meal fatty acid composition on non-fasting
inflammatory biomarkers, the data thus far remain inconsist-
ent(73). It has been reported that in overweight men, plasma
IL-6, TNF-a and soluble vascular adhesion molecule-1 concen-
trations decreased after an n-6 PUFA-rich meal, while markers
were increased after a SFA-rich meal(74). In contrast, Manning
et al.(75) showed that high-fat meals increased IL-6, indepen-
dent of the type of fatty acid, and had no impact on IL-8
and TNF-a concentrations.
Dietary carbohydrates and inflammation
Besides postprandial lipaemia, postprandial glucose is
an independent predictor of diabetes and CVD, an effect
which may be mediated through oxidative stress and
inflammation(76). Importantly, there appears to be no
glycaemic threshold for reduction of either microvascular or
macrovascular complications. The progressive relationship
between plasma glucose and the risk of CVD extends well
below the diabetic threshold(77,78).
Acute glucose variations from peaks to nadirs include
postprandial glucose excursions that can be described
by two components. The first component, which is the
duration of the postprandial glucose increment, is a major
contributor to chronic sustained hyperglycaemia, while the
second component, which is the magnitude of the post-
prandial rise, is more often a reflection of glucose variability.
It is difficult to discriminate between the contributions of
these two components of dysglycaemia. It seems that
both contribute to the two main mechanisms that lead to
diabetic and cardiovascular complications, namely excessive
protein glycation and activation of oxidative stress and
inflammation.
Although mechanistic evidence indicates a positive corre-
lation between the glycaemic index and load of the diet and
low-grade inflammation, intervention studies, to date, do not
convincingly support this. Hu et al.(79) observed a stepwise
relationship between dietary glycaemic index and oxidative
stress markers in healthy adults. Furthermore, high-glycaemic
index carbohydrates increase NF-kB activation and NF-kB
binding in mononuclear cells of young, lean healthy
subjects(80). Diets low in glycaemic load and high in whole
grains may have a protective effect against systemic
inflammation in diabetic patients, as reviewed elsewhere(81).
Consistent with this, epidemiological studies have shown an
inverse relationship between dietary fibre and CRP levels.
Both the DASH diet (naturally high in fibre, i.e. 30 g fibre/d)
and a fibre-supplemented usual diet (30 g psyllium fibre/d)
decreased CRP concentrations in lean normotensive
subjects(82). In contrast, a high-carbohydrate, low-fat diet
with a relatively high dietary fibre and complex carbohydrate
content, within the context of a lifestyle intervention
programme, has been shown to reduce diabetes incidence
in the long term by 50 %(83). The prominent role of the type
of carbohydrate has also been illustrated in studies showing
that dietary carbohydrate modification, i.e. an oat/wheat/
potato diet, up-regulated sixty-two genes related to stress,
cytokine–chemokine-mediated immunity and IL pathways
compared with a rye–pasta diet(84). These differences in the
inflammatory response have been ascribed to differences in
the early insulin response and the resultant late hypogly-
caemia in the oat/wheat/potato group.
Taken together, studies have suggested that healthy eating
patterns characterised by reduced postprandial glycaemia
and lipaemia are associated with reduced concentrations of
markers of low-grade inflammation.
Low-grade inflammation, diet and health 5
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Plant bioactive compounds and inflammation
Recent prospective cohort data suggest that improved
cognitive function and a reduced risk of age-related neuro-
degenerative diseases, associated with increased fruit and
vegetable intake(85–87), may be in large part attributable to
intake of specific flavonoids(87), and may involve an effect
on inflammatory processes (Table 1). In particular, increased
consumption of total flavonoids was positively associated
with episodic memory in middle-aged adults(88) and with a
reduced rate of cognitive decline in adults aged 70 years
and over(89). The anthocyanin group of flavonoids, with cer-
tain soft fruits providing the most significant dietary source,
has emerged as being particularly potent. In the Nurses’
Health Cohort, greater intakes of blueberries and strawberries
were associated with slower rates of cognitive decline, with a
high intake of soft fruits estimated to delay cognitive ageing by
up to 2·5 years(90). Furthermore, a large cross-sectional study
has also indicated that total flavonoid intake is inversely corre-
lated with serum CRP concentrations(91). In support of this
association, a number of dietary intervention studies have
provided evidence that dietary flavonoids are capable of
modulating inflammatory cytokines (e.g. TNF-a) and CRP
production(91–94). However, there are relatively few human
RCT investigating the anti-inflammatory and cognitive effects
of flavonoids (Table 1).
Although the effects of flavonoids were originally ascribed
to an antioxidant action, it is now clear that levels achieved
in biological tissues may not be sufficient to act in this way.
Evidence indicates that flavonoids are capable of acting in
a number of other ways that may result in their targeting
of inflammation, including (1) the modulation of intracellular
signalling cascades that control neuronal survival, death and
differentiation; (2) an impact on gene expression and (3) inter-
acting with the mitochondria(95–98). In particular, emerging
evidence suggests that dietary flavonoids may exert neuro-
protective effects by suppressing the activation of microglia,
which mediate inflammatory processes in the CNS (see the
earlier section). Although rather complex, the main anti-
inflammatory properties of flavonoids include (1) an
inhibitory role in the release of cytokines, such as IL-1b and
TNF-a, from activated microglia; (2) an inhibitory action
against inducible NO synthase induction and subsequent NO
production in response to glial activation; (3) an ability to
inhibit the activation of NADPH oxidase and subsequent
generation of reactive oxygen species in activated glia;
and (4) a capacity to down-regulate the activity of pro-inflam-
matory transcription factors, such as NF-kB, through their
influences on a number of glial and neuronal signalling
pathways(99,100). However, almost all mechanistic studies
have been carried out in vitro at rather supraphysiological
concentrations, with limited research on animal models and
scarce data from human RCT.
Early-life nutrition and inflammation
During development, the human embryo and fetus undergo
an enormously complex series of changes in both cell type T
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and cell number. Each of these changes takes place in a strictly
choreographed series, and disruption of the process can lead
to dramatic and long-lasting consequences. There are
many recent summaries of the processes involved(101). In
humans, this was most clearly demonstrated in the Second
World War, when Dutch women were placed under famine
conditions following a railway workers’ strike (the Dutch
Hunger Winter)(102,103). Studies on the offspring of women
who were pregnant at this time have shown clearly that
women who were pregnant in the first trimester gave birth
to babies who would go on to develop a much wider spec-
trum of health problems than babies born to women who
were in the second or third trimester, though these offspring
still would continue to show health problems(104).
Factors other than undernutrition can also have both short-
and long-term consequences. Of particular relevance, obese
women give birth to babies with a higher risk of both small
for gestational age and large for gestational age, of compli-
cations at birth and of developing the MetS(105,106). All these
cannot be explained by postnatal events, and are at least
partly explained by the phenomenon known as ‘fetal
programming’ or ‘developmental programming’(107,108). This
hypothesis states that nutrition-related exposures in utero
‘programme’ the baby to expect a postnatal nutritional
environment, and if a different one is experienced, then
there is a risk of the development of metabolic complications.
There have been refinements to the basic hypothesis and to
our understanding of the mechanisms involved(109–112); how-
ever, the fundamental observations remain unchanged and
unchallenged. How these associations are mediated is not
yet clearly demonstrated, but several hypotheses are being
tested. There is substantial support for nutrition altering the
epigenetic profile of the offspring, including hypermethylation
of cytokine receptors. Evidence indicates that low Fe status at
birth, which is associated with impaired lung function in chil-
dren, can result in reduced nephron number and decreased
levels of cell-cycle enzymes(113), suggesting that nutritional
deficiency during a critical phase of development can inhibit
organ growth. This fits with data showing that thymus
growth is reduced, and that this leads to changes in the
cytokine profile.
Maternal obesity also has dramatic effects on pregnancy
outcome. Again, there are many detailed reviews dealing
with this topic(107). The mechanisms seem to involve inflam-
matory responses, and increased cytokine levels have been
reported in the placenta and cord blood of babies born to
obese mothers. Whether, in humans, the placenta alone is
responsible is not clear, and it is quite likely that adipose
tissue itself, which becomes infiltrated with macrophages,
will produce increased amounts of pro-inflammatory cyto-
kines(114). The situation becomes more complex in obesity,
because in addition to the cytokines, or possibly because of
the cytokines, inflammation results in changes in Fe metab-
olism(115), and there is abundant evidence to show that
decreased Fe status during pregnancy has adverse effects on
the offspring(116–119). Obesity results in increased hepcidin
production(120,121). Hepcidin is a negative regulator of Fe
absorption(122), and lower Fe status in the mother before
birth is associated with an increased risk of wheezing in the
children (W Bright, G Devereux, HJ McArdle, unpublished
results). Thus, decreased Fe status may be an additional risk
factor in obese mothers.
Translating research into public health benefit and
novel products
Biomarkers of inflammation in human nutrition studies
As explained previously, inflammation is a normal process,
and there are a large number of cells and mediators involved;
measurement of these is often used as a ‘biomarker’ of inflam-
mation, i.e. an indicator that inflammation is occurring. These
cells and mediators are largely involved in, or are produced as
a result of, the inflammatory process, irrespective of the trigger
or its location in the body, and are common to all inflamma-
tory situations(1). To monitor inflammation in a meaningful
way, the markers used must be valid: they must reflect the
inflammatory process under study and must be predictive of
future health status. The range of potential biomarkers of
inflammation was considered by an Expert Group of ILSI
Europe, with the aim of identifying robust and predictive mar-
kers, or patterns or clusters of markers, which can be used to
assess inflammation in human nutrition studies in the general
population; markers indicative of a specific inflammatory
pathology (e.g. rheumatoid arthritis) and/or in less accessible
tissue sites (e.g. in lung lavage fluid or in intestinal biopsy
material) were not considered to be relevant to more healthy
populations(7). Currently, there is no consensus as to which
markers best represent low-grade inflammation(6), or differen-
tiate between acute and chronic inflammation or between the
various phases of inflammatory responses(7). Therefore, a
range of blood cellular markers (e.g. total leucocytes, granulo-
cytes and activated monocytes) and soluble mediators (cyto-
kines and chemokines (TNF, IL-1, IL-6, IL-8, CC chemokine
ligand 2 (CCL2), CCL3, CCL5), adhesion molecules (vascular
cell adhesion molecule-1, intercellular adhesion molecule-1,
E-selectin), adipokines (adiponectin) and acute-phase
proteins (CRP, serum amyloid A, fibrinogen)) are frequently
measured. Some of these are associated with future risk of
CVD and with cardiometabolic health(1,6,7). However, there
are several key issues concerning the use of these markers
as determinants of low-grade inflammation. First, they are
non-specific acute-phase response and pro-inflammatory
response markers, and, by themselves, do not represent
metabolic low-grade inflammation. Second, even in healthy
individuals, there is wide variation in the measurements
made. This is because there are a number of modifying factors
that affect the concentration of an inflammatory marker at a
given time. These modifying factors include age, diet, body
fatness, physical fitness and genetics, among others(1).
One can question whether static measurements of single or
complex biomarkers are truly informative about health status,
reasoning from the concept that health is defined by the ability
to adequately adapt to everyday challenges(123). Measuring the
concentration of inflammatory markers in the bloodstream
under basal conditions is probably less informative and
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relatively insensitive compared with measurements of the
concentration change in response to a challenge. A number
of inflammatory challenges have been described. These
include an oral glucose load(80), an oral fat load(124,125),
acute exercise, administration of bacterial LPS(126), exposure
to UV irradiation(127,128) and vaccination. Although each of
these challenges has been used in nutritional studies, many
are poorly standardised, limiting the comparisons that can
be made. Most often, the markers measured in response to
challenges are those mentioned earlier in the context of
static basal measurements. Currently, a number of large
European consortia, i.e. PhenFlex (http://www.nugo.org/
everyone/42 701/7/0/30), NutriTech (http://www.nugo.org/
nutritech) and BioClaims (http://bioclaims.uib.es), are devel-
oping and validating the metabolic challenge test concept
for application in the assessment of health status, including
the study of inflammatory process markers(129).
The past decade has seen huge growth in innovation
in ‘omics’ technologies that provide enormous opportunities
for high-throughput biological sample characterisation, with
patterns and clusters of markers (signatures or fingerprints)
emerging as robust biomarkers of inflammation(89,130). The
enormous challenge in this era of big data is making biological
sense of different levels of data, including the transcriptome,
proteome, metabolome and clinical chemistry data. Novel
data analysis methodologies, such as machine learning,
offer large potential for identifying relevant data for specific
biological outcomes based on complex multidimensional
datasets(131). In addition, bioinformatic tools have been devel-
oped to interpret these complex data in the context of existing
biological knowledge in the literature and databases, also
termed network biology(132,133). These technologies will be
instrumental to the discovery of relevant biomarker signatures
that reflect ‘low-grade inflammation’ based on inflammatory
response networks connected to organ-specific metabolic
derailment.
With the coming of age of the ‘omics’ technologies and
bioinformatic tools, a large increase in the number, specificity
and sensitivity of candidate biomarkers of inflammation can
be expected in the next decade(134). A screening of the ‘Thom-
son Reuters IntegritySM Biomarker Database’ reveals that as of
May 2014, 945 candidate biomarkers of inflammation have
been described, of which only seventeen, including CRP,
TNF-a, serotransferrin and erythrocyte sedimentation rate,
have been developed into biomarker assays approved and
recommended by regulatory bodies for use in clinical studies.
This represents the classical biomarker gap: many candidate
biomarkers are identified based on preclinical and clinical
studies; however, due to relatively limited efforts in validation
and assay development, these are subsequently not further
developed(135). To accelerate biomarker development, a para-
digm shift in this area is needed; instead of single companies
developing a single biomarker assay, pre-competitive collab-
orations between different industrial, academic, and research
and technology organisations have the advantage of a more
efficient development process time- and cost-wise, by com-
bining a wide diversity of expertise, in the development of
a harmonised, standardised and accepted assay. In these
consortia, ideally, companies from nutrition, pharma and
diagnostics join forces in a pre-competitive way.
A major concerted effort should comprise (1) the discovery
of context-based biomarker signatures for the assessment of
the status of low-grade inflammation, (2) the development
of challenge tests that determine the inflammatory response
functionality in the context of metabolic stress-induced
low-grade inflammation, and (3) the development of the
identified biomarkers towards application in a clinically
accepted assay, with normative data.
Low-grade inflammation and health claims
The European Food Safety Authority (EFSA) guidance docu-
ment on scientific requirements for health claims related to
gut and immune function(136) specifically states that chronic
inflammation is associated with the development of a
number of diseases, and that ‘altering levels of markers of
inflammation might indicate a beneficial effect in the context
of “a reduction of disease risk claim”, if it can be demonstrated
that altering the levels of inflammatory markers is
accompanied by a reduced incidence of a disease for a
specific dietary intervention’. No additional specificity is
added for chronic low-grade inflammation. At present, the
European Union health claim register (http://ec.europa.eu/
nuhclaims) does not contain any authorised or non-authorised
health claims that specifically address the health benefit area
of suppression or control of low-grade inflammation.
To build strong health claims on nutrition for improving
inflammation control in the future, one of the key focus
areas should be the need for clinically relevant prognostic
marker(s) or marker signatures that reflect the inflammatory
state in a context-specific manner, which have been well vali-
dated and for which a robust standardised assay is available.
The lack of health claims is probably attributable to the fact
that, although numerous biologically plausible mechanisms
have been established to explain inflammation–disease
associations, no single biomarker or cluster of biomarkers
of inflammation has yet been robustly demonstrated to be
sufficiently predictive of future disease. Based on the EFSA
guidance on this topic(136) and the classification of candidate
biomarkers as described by the expert group of ILSI
Europe(137), the suggested strategy for building a EFSA
health claim dossier (Fig. 2) comprises (1) a definition of the
composition of the product; (2) a well-founded selection of
the target population; (3) the selection of a clinically relevant
composite biomarker panel representing inflammation as well
as the selected health benefit (or disease risk) endpoints; and
(4) a number of sufficiently powered and well-controlled
human studies assessing the effect of the test material (nutri-
ent, food, product) on the relevant biomarkers in the relevant
target population.
Summary and suggestions for the way forward
Inflammation is a normal component of host defence;
however, elevated unresolved chronic inflammation is a core
perturbation in a range of chronic diseases and is an important
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determinant of the pathological impact of excess adiposity.
Cell, animal and human epidemiological studies have
identified a number of potential diet derived anti- and
pro-inflammatory components, some of which have been dis-
cussed here; this topic has been dealt with more extensively
elsewhere(1,6,7). Available human RCT evidence is more
limited and sometimes conflicting or inconsistent, in part
attributable to under-powered studies where inflammation
was not specified as a primary study outcome. Furthermore,
research tends to take a reductionist approach and examine
the impact of individual dietary components in isolation,
despite the identification of numerous potential diet-derived
anti-inflammatory and inflammation-resolving bioactive com-
pounds, with likely additive or synergistic effects. There is a
need to take a more holistic approach and consider the
impact of combinations of components of foods and dietary
patterns, with a likely greater overall benefit than each
single component might have on its own. Moreover, although
it is evident that the inflammatory response is highly variable,
a full understanding of the source of heterogeneity is distinctly
lacking. More extensive profiling of participants in human
studies and consideration of potential key variables such as
age, sex, genotype and lifestyle factors in statistical models
is needed in order to help understand the aetiology of the
variation in both inflammation itself and in its response to diet-
ary change. This approach will also allow for the identification
of population subgroups that may particularly benefit from
interventions that target inflammation.
Product
Target population
Biomarkers
Study design
Clinically relevant (surrogate)
health endpoint (group B) 
Definition of relevant biomarkers
Significant modulation of markers
by a specified nutritional
component in multiple studies
Study design of studies included in
the dossier: RCT, cross-over, males
and females fitting the target
population
Definition of the composition
of the nutritional component
Inflammation markers associated
with clinical relevance, or
mechanistic markers (group C/D)
Inflammation marker with
clinical relevance (group A)
Susceptible population
Reduction of disease claim 14·1
Functional claim for the general
population
Functional claim 13·1/13·5
Evidence of a strong correlation of
inflammation biomarker with
disease (risk) based on public data
Quality of study design of studies
included in the dossier: design fit to
purpose, power, statistical
evaluation
EFSA health claim
Definition of the target population
Assessment of
safety
Fig. 2. Schematic of topics to be addressed when building a dossier for a European Food Safety Authority (EFSA) health claim on control of chronic low-grade
inflammation. The blue boxes indicate the main topics to be addressed; the white boxes state the actual content topics. Building a strong EFSA health claim
dossier requires (1) a definition of the composition of the nutritional component including manufacturing procedures in scope and out of scope for the claim, (2) a
clear definition of the target population, being the general population or a specific subpopulations at risk, including the defining parameters, (3) a definition of bio-
markers measured to assess the health effects of the nutritional component, including a description of the proof of clinical relevance, or the clinical validity of the
combination of inflammation biomarkers and related clinically relevant biomarkers for health benefit endpoints associated with the health claim, and (4) a full
description of clinical study design for all studies included in the dossier, including statistical power analysis and safety evaluation. The red arrow indicates the
primary hurdle for functional health claims in the area of chronic low-grade inflammation, which is the lack of (combinations of) inflammation biomarkers with estab-
lished and therefore accepted clinical relevance. This is primarily the consequence of inflammatory responses being non-specific normal physiological responses to
tissue damage, and discrimination between normal and abnormal levels or combinations has not been well established in relation to chronic low-grade inflammation.
The description of the classification of clinical relevance of biomarkers (categories A–D) was adapted from Albers et al.(137). RCT, randomised controlled trial.
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Establishing and quantifying reliable, precise diet–
inflammation–health associations is reliant on the availability
of approved, standardised biomarkers with normative data
for use in human observation studies and RCT. Biomarker
research is a highly active area with significant advances to
be expected in the coming years(138). Rather than rely on a
limited number of generic markers common to both acute
and low-grade chronic inflammation, future inflammation
‘testing’ is likely to involve quantifying clusters or signatures
of markers with some tissue specificity. Such biomarkers
should generally be measured in the challenged state(1),
with the choice of the physiological stressor dependent on
the tissue, and research question of interest. The biomarkers
assessed are likely to include those already typically
measured (cytokines, chemokines, soluble adhesion
molecules, etc.), but are also likely to include tissue-specific
markers and fingerprints based on gene expression profiles
(e.g. in blood mononuclear cells), cell or plasma proteomics,
and microRNA.
The research focus on the establishment of a robust
diet–inflammation–health association is justifiable, consider-
ing the substantial role of low-grade inflammation in the path-
ology of numerous chronic diseases, thereby making it a key
future preventative and therapeutic target.
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